Our top pick for
Lantern Pharma Inc is a biotechnology business based in the US. Lantern Pharma shares (LTRN) are listed on the NASDAQ and all prices are listed in US Dollars. Lantern Pharma employs 11 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$10.24|
|52-week range||$9.00 - $23.50|
|50-day moving average||$11.89|
|200-day moving average||$13.93|
|Wall St. target price||$29.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.11|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||2.40%|
|1 month (2021-09-21)||-12.33%|
|3 months (2021-07-21)||-25.85%|
|6 months (2021-04-21)||-30.67%|
|1 year (2020-10-21)||-38.54%|
|2 years (2019-10-17)||N/A|
|3 years (2018-10-17)||N/A|
|5 years (2016-10-17)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-11.02%|
|Return on equity TTM||-18.22%|
|Market capitalisation||$112 million|
TTM: trailing 12 months
There are currently 234,027 Lantern Pharma shares held short by investors – that's known as Lantern Pharma's "short interest". This figure is 10.9% down from 262,722 last month.
There are a few different ways that this level of interest in shorting Lantern Pharma shares can be evaluated.
Lantern Pharma's "short interest ratio" (SIR) is the quantity of Lantern Pharma shares currently shorted divided by the average quantity of Lantern Pharma shares traded daily (recently around 62407.2). Lantern Pharma's SIR currently stands at 3.75. In other words for every 100,000 Lantern Pharma shares traded daily on the market, roughly 3750 shares are currently held short.
However Lantern Pharma's short interest can also be evaluated against the total number of Lantern Pharma shares, or, against the total number of tradable Lantern Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lantern Pharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Lantern Pharma shares in existence, roughly 20 shares are currently held short) or 0.0396% of the tradable shares (for every 100,000 tradable Lantern Pharma shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lantern Pharma.
Find out more about how you can short Lantern Pharma stock.
We're not expecting Lantern Pharma to pay a dividend over the next 12 months.
Lantern Pharma Inc. , a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.